To compare RNA expression between treated and untreated cells, which workflow is appropriate?
A measure total antibody by ELISA
B isolate RNA, reverse-transcribe it to cDNA, then quantify with real-time PCR
C amplify the RNA directly with DNA polymerase alone
D sequence a protein after Western blot
Answer: B. isolate RNA, reverse-transcribe it to cDNA, then quantify with real-time PCR. RT-qPCR requires reverse transcription before DNA amplification and real-time quantification.
Which qPCR control helps detect contamination introduced during reaction setup?
A a no-template control
B an uninfected cell culture with no PCR reagents
C a protein ladder
D a positive sample only
Answer: A. a no-template control. A no-template control contains reaction reagents but no target template and should not amplify.
Suppose two samples are tested with the same validated qPCR assay and one crosses threshold several cycles earlier. The earlier sample likely had
A more antibody but no nucleic acid
B less starting target nucleic acid
C more starting target nucleic acid
D no target at all
Answer: C. more starting target nucleic acid. Earlier threshold crossing generally corresponds to higher starting template under comparable conditions.
A diagnostic lab must detect an antigen when the sample may contain many unrelated proteins. Why use a capture antibody plus a second antibody?
A two antibodies amplify DNA directly
B two specific binding steps improve target recognition in a sandwich assay
C the antibodies convert antigen into RNA
D the second antibody prevents all nonspecific binding by itself
Answer: B. two specific binding steps improve target recognition in a sandwich assay. A sandwich design uses capture and detection antibodies to recognize the target at distinct binding sites.
A genetic test detects a variant in a tumor sample but not in blood cells. Which interpretation is plausible?
A the variant may be somatic and limited to tumor cells
B the blood test proves the tumor result false
C the sample contains no DNA
D the variant must be inherited by every cell
Answer: A. the variant may be somatic and limited to tumor cells. Somatic mutations can be present in tumor tissue without being inherited or detectable in normal blood cells.
A laboratory measures a biomarker in a small cohort and obtains a promising result. What is the best next step before clinical use?
A announce a diagnosis from the pilot alone
B assume the result applies to every population
C validate the assay and result in independent, appropriately designed cohorts
D remove the negative controls
Answer: C. validate the assay and result in independent, appropriately designed cohorts. Independent validation is needed before a biomarker is used for clinical decisions.
A new PCR assay amplifies a related but nontarget gene. Which assay property is inadequate?
A sample volume
B sensitivity
C cell viability
D analytical specificity
Answer: D. analytical specificity. Cross-amplification indicates insufficient analytical specificity for the intended target.
A patient sample tests negative for target DNA, but the internal amplification control also fails. How should the result be handled?
A as a positive antibody result
B as proof of immunity
C as invalid or inconclusive, then investigate inhibition or processing failure
D as a definitive negative
Answer: C. as invalid or inconclusive, then investigate inhibition or processing failure. Failure of an internal control means the assay may not have worked properly, so the negative target result is not reliable.
A DNA microarray includes probes for known variants. Which limitation follows from this design?
A it edits the tested DNA
B it always detects every possible mutation
C it directly measures protein activity
D it may miss variants not represented by probes
Answer: D. it may miss variants not represented by probes. Microarrays depend on available probes and may miss unrepresented sequence changes.
An NGS test reports a variant of uncertain significance. Which action best supports responsible interpretation?
A review evidence and avoid treating uncertainty as a confirmed diagnosis
B label it pathogenic without follow-up
C ignore quality metrics
D assume every rare variant causes disease
Answer: A. review evidence and avoid treating uncertainty as a confirmed diagnosis. Variant interpretation should integrate evidence, quality, and clinical context; uncertain findings are not confirmed pathogenic results.
A patient-specific therapy uses the patient’s own cells. Which term describes the cell source?
A xenogeneic
B syngeneic plant
C autologous
D allogeneic
Answer: C. autologous. Autologous cells come from the same individual who receives them.
A donor-derived cell product is given to a different patient. It is
A autologous
B pluripotent by definition
C allogeneic
D monoclonal
Answer: C. allogeneic. Allogeneic products use cells from a genetically distinct donor of the same species.
A CAR-T product is genetically modified ex vivo. Which release tests are especially relevant?
A leaf shape and chlorophyll
B identity, viability, potency, sterility, and genetic modification
C only the patient’s blood type
D the donor’s eye color
Answer: B. identity, viability, potency, sterility, and genetic modification. Cell therapy release testing assesses identity, safety, viability, potency, and intended modification.
A gene-therapy vector is designed to deliver a normal copy of a gene to somatic cells. Which outcome is intended?
A restore or supplement the function of the affected cells
B make the target cells produce antibodies against every protein
C remove all immune memory
D edit every germ cell in the patient
Answer: A. restore or supplement the function of the affected cells. Gene addition can provide a functional copy to cells, though outcomes depend on delivery and expression.
An immune response against a viral vector reduces transduced-cell persistence. Which design concern should be considered?
A whether the patient has plant allergies
B the number of PCR primers in a separate diagnostic assay
C the fluorescence of a DNA ladder
D pre-existing or induced immunity to the vector
Answer: D. pre-existing or induced immunity to the vector. Vector immunity can affect delivery, persistence, and safety.
In a cell-therapy potency assay, what is being measured?
A the color of the shipping container
B the number of labels on the vial
C the patient’s genome sequence only
D whether the product performs its intended biological function
Answer: D. whether the product performs its intended biological function. Potency assays evaluate a cell product’s intended biological activity.
An ELISA’s negative control gives a strong signal. Which problem is most likely?
A nonspecific binding, contamination, or inadequate washing
B the antigen is definitely absent
C the standard curve is unnecessary
D the test has perfect sensitivity
Answer: A. nonspecific binding, contamination, or inadequate washing. A strong negative-control signal suggests background, contamination, or assay-process problems.
A pharmacogenomic test finds a variant that changes enzyme activity. What information can it support?
A a definitive diagnosis of every disease
B proof that a drug will work in every patient
C a prediction about drug metabolism that may inform treatment choices
D the exact concentration of a drug without measuring it
Answer: C. a prediction about drug metabolism that may inform treatment choices. Pharmacogenomic results can inform, but do not alone determine, medication response.
A qPCR standard curve is used to estimate target quantity. What relationship is calibrated?
A protein band location versus pH only
B cycle threshold versus known template concentrations
C antibody color versus cell size
D vessel volume versus DNA sequence
Answer: B. cycle threshold versus known template concentrations. A standard curve relates Ct values to known target amounts for quantification within assay limits.
A diagnostic study has many healthy participants but few affected cases. Which performance measure may be estimated imprecisely?
A PCR cycle temperature
B sensitivity
C reagent volume
D sample storage time
Answer: B. sensitivity. Sensitivity depends on the number and representation of true-positive cases in the study.
A test is used to screen a low-prevalence population. Why can many positive results still be false positives even with good specificity?
A positive predictive value depends on prevalence as well as test performance
B the test begins amplifying unrelated proteins
C prevalence never affects interpretation
D sensitivity becomes zero
Answer: A. positive predictive value depends on prevalence as well as test performance. When prevalence is low, false positives can comprise a larger share of all positive results.
A recombinant protein has the correct amino-acid sequence but poor activity. Which factor should be examined?
A whether the gene has a stop codon in the DNA ladder
B the color of the bacterial colony only
C folding, processing, and post-translational modifications
D the number of microscope slides
Answer: C. folding, processing, and post-translational modifications. Protein function can depend on folding and processing in addition to sequence.
A therapeutic monoclonal antibody is glycosylated differently from the reference product. Why can this matter?
A it guarantees identical potency
B it removes the need for clinical evaluation
C it changes the antibody into DNA
D glycosylation can affect biological activity or other product properties
Answer: D. glycosylation can affect biological activity or other product properties. Post-translational modifications can influence biologic activity, stability, and product characteristics.
A gene therapy product is intended for one organ, but vector DNA is detected elsewhere. What should be assessed?
A only the intended organ’s color
B biodistribution and off-target exposure
C the patient’s blood group alone
D the PCR thermocycler brand
Answer: B. biodistribution and off-target exposure. Biodistribution studies evaluate where the vector or genetic payload reaches.
An edited cell product contains unintended genomic changes. Which quality concern is raised?
A cryopreservation temperature of a different product
B ELISA signal amplification
C antibody specificity only
D genomic integrity and off-target effects
Answer: D. genomic integrity and off-target effects. Unintended edits require assessment of genomic integrity and possible functional consequences.